ArticleESC heart failure2025
Haemodynamic consequences of acute pulmonary embolism predict risk of CTPA-related acute kidney injury.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comparison of pulmonary ventilation/perfusion tomography and conventional diagnostic techniques in the diagnosis of pulmonary thromboembolism.Journal of thoracic disease · 2026Article
- Haemodynamic consequences of acute pulmonary embolism predict risk of CTPA-related acute kidney injury.ESC heart failure · 2025Article
- Letter to the Editor, 'Haemodynamic consequences of acute pulmonary embolism predict risk of CTPA-related acute kidney injury'.ESC heart failure · 2025Article
- The utility of urine biomarkers in diuretic resistance prediction in heart failure hospitalization.ESC heart failure · 2025Article
- Article
- Plasma lactate and severity of illness for acute pulmonary embolism: A Bayesian probability model.International journal of critical illness and injury scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionComputed tomography pulmonary angiography (CTPA) is an important study in the diagnosis of acute pulmonary embolism (APE). There are limited data on acute kidney injury (AKI) after CTPA in APE patients. The aim was to evaluate frequency and predictors of AKI in patients with the first APE episode. PATIENTS AND
methodsSingle-centre, retrospective analysis of APE patients, without haemodynamic instability. Blood tests, including plasma creatinine concentration and clinical evaluation were performed before CTPA and after 48 and 72 h. Transthoracic echocardiography was performed to evaluate right ventricular (RV) function.
resultsA total of 411 patients with APE were enrolled. AKI defined by creatine increase ≥0.3 mg% within 72 h following CTPA was found in 46 pts (11.2%). Patients with AKI (+) when compared with AKI (-) were characterized by higher sPESI score; more pronounced RV dysfunction; higher plasma concentration of N terminal pro brain natriuretic peptide (NT-proBNP) and more often suffered from pre-existing chronic kidney disease (CKD) and diabetes mellitus (DM2). The multivariate logistic regression model showed that only: BOVA score {odds ratio (OR) 1.431 [95% confidence interval (CI), 1.110; 1.845], P value = 0.006}; NT-proBNP > 3314 pg/mL [OR 3.765 (95% CI, 1.572; 9.016), P value = 0.003], while not CKD or sPESI were independent risks factors for AKI. Among subjects with BOVA ≥ 3 points and NT-proBNP ≥ 3314 pg/mL, almost 32% developed AKI, and among patients with BOVA < 3 points and NT-proBNP < 3314 pg/mL, only 5% of patients developed AKI.
conclusionsAKI present in 11% of all PE patients diagnosed with CTPA is associated with embolism severity, measured by BOVA score, and RV dysfunction as defined by higher NT-proBNP, while not to pre-existing CKD or DM2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.